カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2018/02/21 | 1,198 | 1,241 | 1,186 | 1,230 | +34 | +2.8% | 86,400 |
2018/02/20 | 1,171 | 1,199 | 1,164 | 1,196 | +5 | +0.4% | 36,300 |
2018/02/19 | 1,184 | 1,199 | 1,175 | 1,191 | +37 | +3.2% | 47,900 |
2018/02/16 | 1,159 | 1,175 | 1,135 | 1,154 | +24 | +2.1% | 50,800 |
2018/02/15 | 1,116 | 1,151 | 1,103 | 1,130 | +1 | +0.1% | 67,200 |
2018/02/14 | 1,160 | 1,194 | 1,102 | 1,129 | -27 | -2.3% | 69,500 |
2018/02/13 | 1,205 | 1,221 | 1,138 | 1,156 | -38 | -3.2% | 128,600 |
2018/02/09 | 1,127 | 1,209 | 1,120 | 1,194 | -23 | -1.9% | 83,700 |
2018/02/08 | 1,194 | 1,224 | 1,155 | 1,217 | +67 | +5.8% | 100,500 |
2018/02/07 | 1,195 | 1,206 | 1,150 | 1,150 | +35 | +3.1% | 107,500 |
2018/02/06 | 1,110 | 1,160 | 1,064 | 1,115 | -126 | -10.2% | 274,700 |
2018/02/05 | 1,295 | 1,312 | 1,240 | 1,241 | -103 | -7.7% | 185,900 |
2018/02/02 | 1,328 | 1,344 | 1,313 | 1,344 | +14 | +1.1% | 45,000 |
2018/02/01 | 1,300 | 1,333 | 1,288 | 1,330 | +38 | +2.9% | 82,800 |
2018/01/31 | 1,287 | 1,305 | 1,265 | 1,292 | +7 | +0.5% | 56,300 |
2018/01/30 | 1,316 | 1,324 | 1,274 | 1,285 | -37 | -2.8% | 110,400 |
2018/01/29 | 1,363 | 1,390 | 1,316 | 1,322 | -41 | -3% | 97,300 |
2018/01/26 | 1,475 | 1,489 | 1,363 | 1,363 | -103 | -7% | 303,800 |
2018/01/25 | 1,400 | 1,482 | 1,386 | 1,466 | +64 | +4.6% | 334,400 |
2018/01/24 | 1,350 | 1,406 | 1,344 | 1,402 | +42 | +3.1% | 200,200 |
2018/01/23 | 1,309 | 1,386 | 1,309 | 1,360 | +21 | +1.6% | 157,000 |
2018/01/22 | 1,259 | 1,353 | 1,259 | 1,339 | +80 | +6.4% | 176,600 |
2018/01/19 | 1,262 | 1,275 | 1,252 | 1,259 | -9 | -0.7% | 53,400 |
2018/01/18 | 1,279 | 1,291 | 1,268 | 1,268 | +3 | +0.2% | 75,700 |
2018/01/17 | 1,303 | 1,305 | 1,265 | 1,265 | -43 | -3.3% | 119,100 |
2018/01/16 | 1,322 | 1,329 | 1,277 | 1,308 | -25 | -1.9% | 278,700 |
2018/01/15 | 1,382 | 1,396 | 1,316 | 1,333 | -43 | -3.1% | 269,500 |
2018/01/12 | 1,366 | 1,424 | 1,345 | 1,376 | -14 | -1% | 298,200 |
2018/01/11 | 1,388 | 1,435 | 1,367 | 1,390 | -88 | -6% | 499,500 |
2018/01/10 | 1,530 | 1,560 | 1,423 | 1,478 | +59 | +4.2% | 2,155,000 |
2018/01/09 | 1,177 | 1,419 | 1,172 | 1,419 | +300 | +26.8% | 1,964,300 |
2018/01/05 | 1,123 | 1,123 | 1,103 | 1,119 | -4 | -0.4% | 55,800 |
2018/01/04 | 1,120 | 1,139 | 1,117 | 1,123 | -5 | -0.4% | 79,400 |
2017/12/29 | 1,103 | 1,130 | 1,101 | 1,128 | +23 | +2.1% | 88,000 |
2017/12/28 | 1,104 | 1,121 | 1,095 | 1,105 | -10 | -0.9% | 98,400 |
2017/12/27 | 1,070 | 1,118 | 1,063 | 1,115 | +56 | +5.3% | 125,500 |
2017/12/26 | 1,061 | 1,088 | 1,052 | 1,059 | -4 | -0.4% | 192,600 |
2017/12/25 | 1,100 | 1,103 | 1,053 | 1,063 | -49 | -4.4% | 223,300 |
2017/12/22 | 1,121 | 1,125 | 1,101 | 1,112 | -15 | -1.3% | 129,400 |
2017/12/21 | 1,139 | 1,152 | 1,125 | 1,127 | -7 | -0.6% | 98,700 |
2017/12/20 | 1,141 | 1,146 | 1,130 | 1,134 | -11 | -1% | 94,500 |
2017/12/19 | 1,136 | 1,149 | 1,136 | 1,145 | -1 | -0.1% | 91,900 |
2017/12/18 | 1,173 | 1,174 | 1,143 | 1,146 | -32 | -2.7% | 120,000 |
2017/12/15 | 1,182 | 1,197 | 1,171 | 1,178 | -10 | -0.8% | 66,500 |
2017/12/14 | 1,170 | 1,188 | 1,170 | 1,188 | +9 | +0.8% | 55,000 |
2017/12/13 | 1,196 | 1,202 | 1,173 | 1,179 | -15 | -1.3% | 84,500 |
2017/12/12 | 1,194 | 1,214 | 1,193 | 1,194 | -5 | -0.4% | 57,500 |
2017/12/11 | 1,183 | 1,202 | 1,172 | 1,199 | +16 | +1.4% | 45,700 |
2017/12/08 | 1,186 | 1,191 | 1,171 | 1,183 | -3 | -0.3% | 27,500 |
2017/12/07 | 1,179 | 1,193 | 1,171 | 1,186 | +7 | +0.6% | 63,400 |
1651~
1700
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム